Gilead Sciences Q1 2025 Earnings: Growth Amid Challenges- Intellectia AI™

# Gilead Sciences' Strategic Growth: First Quarter 2025 Earnings Report

## Gilead Sciences Inc. Earnings

Gilead Sciences Inc. has reported its financial results for the first quarter of 2025, showcasing a steady performance despite challenges in certain product segments. Daniel O'Day, Gilead's Chairman and CEO, attributed this strong start to the year to excellent commercial and clinical execution, along with disciplined expense management. The company's robust performance was buoyed by the sustained success of its HIV treatment Biktarvy and positive clinical developments in its oncology pipeline.

## Gilead Sciences Inc. Results

Here's a detailed look at Gilead's key financial metrics for the first quarter of 2025:

| Metric                          | Q1 2025 ($B) | Q1 2024 ($B) | Year-over-Year Change |
|---------------------------------|--------------|--------------|-----------------------|
| Total Revenue                   | 6.7          | 6.7          | Flat                  |
| Product Sales                   | 6.6          | 6.7          | -1%                   |
| Non-GAAP EPS                    | 1.81         | (1.32)       | N/A                   |
| GAAP EPS                        | 1.04         | (3.34)       | N/A                   |
| Operating Cash Flow             | 1.8          | N/A          | N/A                   |
| Cash and Cash Equivalents (EOQ) | 7.9          | 10.0         | N/A                   |

**Note**: N/A denotes data not explicitly provided.

## Revenue Breakdown

The following table provides insight into revenue performance across Gilead’s primary segments:

| Segment                        | Q1 2025 Revenue ($B) | Q1 2024 Revenue ($B) | Change (%) |
|--------------------------------|----------------------|----------------------|------------|
| Product Sales Excluding Veklury | 6.3                  | 6.0                  | 4%         |
| HIV Products                   | 4.6                  | 4.3                  | 6%         |
| Biktarvy Sales                 | 3.1                  | 2.9                  | 7%         |
| Liver Disease Portfolio        | 0.758                | 0.736                | 3%         |
| Veklury (Remdesivir)           | 0.302                | 0.549                | -45%       |
| Cell Therapy                   | 0.464                | 0.478                | -3%        |

In-depth analysis reveals that Gilead maintained stable overall revenue with a total of $6.7 billion. This flat performance compared to the prior year can be attributed to a strong showing in the HIV and liver disease portfolio, offset by a notable decline in Veklury sales due to reduced COVID-19 hospitalizations. Notably, Biktarvy's sales climbed by 7% year-over-year, reflecting sustained demand for the product.

The decline in Veklury sales by 45% from the previous year played a pivotal role in the overall dip in product sales. On the positive side, the liver disease segment witnessed a 3% uptick, benefiting from increased demand for treatments for conditions like chronic hepatitis B and delta viruses. Gilead's cell therapy business showed a slight downturn, primarily due to reduced U.S. demand, despite global growth.

## Key Developments

The first quarter of 2025 also marked several significant developments for Gilead. The company announced positive Phase 3 results for Trodelvy in combination with pembrolizumab for treating PD-L1+ metastatic triple-negative breast cancer, a development that could extend its oncology momentum. Additionally, the upcoming PDUFA date for lenacapavir for HIV prevention signals potential growth opportunities in Gilead’s virology segment.

## Comments from Company Officers

Daniel O'Day, Gilead’s Chairman and CEO, emphasized the firm’s strong commercial and clinical execution: "Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management. Our base business grew 4% year-over-year, primarily led by Biktarvy's continued strength, and we announced positive topline Phase 3 results for Trodelvy in oncology."

## Dividends and Share Repurchases

Gilead continues to reward its shareholders with robust dividend policies and share repurchase programs. During the first quarter, the company returned $1.0 billion through dividends and repurchased $730 million in common stock. Additionally, Gilead repaid $1.8 billion worth of Senior Notes, reflecting its commitment to maintaining a strong balance sheet while returning value to shareholders.

## Gilead Sciences Inc. Stock Forecast

Looking forward, Gilead’s stock picture remains both promising and challenging, shaped by its steady HIV and liver disease businesses and clinical progress in oncology. Given the current market cap of approximately $85.75 billion, potential highs could be seen reflecting continued growth in Biktarvy and anticipated approvals for lenacapavir. Should these materialize, stock prices could trend towards higher valuations. Conversely, lingering uncertainties surrounding Veklury demand and competitive pressures in cell therapy signal potential headwinds, which may place the stock on a lower trajectory if not addressed.

In conclusion, Gilead Sciences Inc. has navigated a challenging landscape with strategic initiatives in place to leverage its clinical successes into broader market opportunities. As 2025 progresses, the company's ability to enhance its virology and oncology pipelines will be crucial to sustaining investor confidence and fostering stock growth.